Excess mortality on the liver transplant waiting list: Unintended policy consequences and model for End-Stage Liver Disease (MELD) inflation

Hepatology

Volumn 61, Issue 1, 2015, Pages 285-291

  Northup, Patrick Grant ^a   Intagliata, Nicolas Michael ^a   Shah, Neeral Lalit ^a   Pelletier, Shawn Joseph ^a   Berg, Carl Lansing ^b   Argo, Curtis Kent ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; END STAGE LIVER DISEASE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEALTH CARE POLICY; HEPATOPULMONARY SYNDROME; HOSPITAL ADMISSION; HUMAN; INBORN ERROR OF METABOLISM; LIVER CELL CARCINOMA; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; UNITED NATIONS; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; SEVERITY OF ILLNESS INDEX;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; WAITING LISTS;

EID: 84920946013     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27283     Document Type: Article

References (14)

1. Merion RM, Wolfe RA, Dykstra DM, Leichtman AB, Gillespie B, Held PJ. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl 2003;9:12-18.
2. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006;6:783-790.
3. Hussong S. Administrative developments: DHHS issues organ allocation final rule. J Law Med Ethics 1999;27:380-382.
4. Washburn K, Edwards E, Harper A, Freeman R. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010;10:1643-1648.
5. Charlton M. The lethal and enduring inequity of deceased donor liver allocation policy for hepatocellular carcinoma in the United States. Am J Transplant 2013;13:2794-2796.
6. Schuetz C, Dong N, Smoot E, Elias N, Schoenfeld DA, Markmann JF, et al. HCC patients suffer less from geographic differences in organ availability. Am J Transplant 2013;13:2989-2995.
7. Wong RJ, Devaki P, Nguyen L, Cheung R, Cho-Phan C, Nguyen MH. Increased long-term survival among patients with hepatocellular carcinoma after implementation of model for end-stage liver disease score. Clin Gastroenterol Hepatol 2013 [Epub ahead of print].
8. Biggins SW, Feng S. In a MELD-based economy, how can we fight off inflation? Liver Transpl 2007;13:2-4.
9. Kim WR, Smith JM, Skeans MA, Schladt DP, Schnitzler MA, Edwards EB, et al. OPTN/SRTR 2012 Annual Data Report: liver. Am J Transplant 2014;14(Suppl 1):69-96.
10. Goldberg D, French B, Abt P, Feng S, Cameron AM. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma. Liver Transpl 2012;18:434-443.
11. Cheng SJ, Freeman RB Jr, Wong JB. Predicting the probability of progression-free survival in patients with small hepatocellular carcinoma. Liver Transpl 2002;8:323-328.
12. Vitale A, Volk ML, De Feo TM, Burra P, Frigo AC, Ramirez Morales R, et al. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol 2014;60:290-297.
13. Piscaglia F, Camaggi V, Ravaioli M, Grazi GL, Zanello M, Leoni S, et al. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. Liver Transpl 2007;13:857-866.
14. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16:262-278.